NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elevance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elevance-health-inc. Investors have until July 11, 2025, to ask the Court to be appointed t ...

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action. Investors have until August 25, 2025, to ask th ...

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action. Investors have until July 22, 2025, to ask the Court to be appointed to lea ...

PHILADELPHIA, July 10, 2025 /PRNewswire/ -- The law firm of Kaskela Law LLC announces that it is investigating Solid Biosciences Inc. (NASDAQ: SLDB) on behalf of the company's shareholders. Since September 2024, shares of Solid Biosciences' stock have declined in value from a trading price of over $10.00 per share to a current trading price of less than $6.00 per share, a decline of over 40% in value. The investigation seeks to determine whether Solid Biosciences and/or the company's officers and directors ...

PHILADELPHIA, July 10, 2025 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating National HealthCare Corporation (NYSE: NHC) ("NHC") on behalf of the company's long-term investors. Since November 2024, shares of NHC's common stock have declined in value from a trading price of over $135.00 per share to a current trading price of below $110.00 per share, a decline of nearly 20% in value. The investigation seeks to determine whether NHC and/or the company's officers and directors violated the se ...

PHILADELPHIA, July 10, 2025 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating MaxLinear, Inc. (NASDAQ: MXL) on behalf of the company's long-term investors. Year to date, shares of MaxLinear's stock are down 25% in value, to trade at a current price of approximately $15.00 per share. The investigation seeks to determine whether MaxLinear and/or the company's officers and directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions. Max ...

Core Viewpoint - The article discusses a class action lawsuit against Sarepta Therapeutics, alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, during a specified class period [1][3]. Company Overview - Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on developing therapies for Duchenne muscular dystrophy, including the gene therapy ELEVIDYS [2]. Allegations of the Lawsuit - The lawsuit claims that Sarepta and its executives made false or misleading statements about ELEVIDYS, including significant safety risks, failure to detect severe side effects, and the potential for halting clinical trials due to adverse events [3]. - Specific incidents cited include: - On March 18, 2025, a patient treated with ELEVIDYS suffered acute liver failure leading to death, causing Sarepta's stock to drop over 27% [4]. - On April 4, 2025, Sarepta disclosed that EU authorities requested a review of the death, leading to a further stock decline of over 7% [5]. - On June 15, 2025, a second patient died from acute liver failure, prompting Sarepta to suspend shipments and pause dosing, resulting in a stock drop of over 42% [6]. - On June 24, 2025, the FDA announced an investigation into the risk of acute liver failure associated with ELEVIDYS, causing an additional stock decline of over 8% [7]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Sarepta securities during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [8].

Core Viewpoint - A class action lawsuit has been filed against iRobot Corporation for allegedly making false and misleading statements regarding its financial stability and restructuring plan during the Class Period from January 29, 2024, to March 11, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that iRobot overstated the effectiveness of its Restructuring Plan following the termination of the Amazon Acquisition, leading to doubts about its ability to operate profitably as a standalone company [5]. - It is alleged that the defendants' public statements were materially false and misleading, which resulted in investor damages when the true information became public [5]. Group 2: Participation Information - Investors who purchased iRobot securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm for more information [3][6]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

SAN DIEGO, July 9, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that the Centene class action lawsuit seeks to represent purchasers or acquirers of Centene Corporation (NYSE: CNC) securities between December 12, 2024 and June 30, 2025, inclusive (the "Class Period"). Captioned Lunstrum v. Centene Corporation, No. 25-cv-05659 (S.D.N.Y.), the Centene class action lawsuit charges Centene and certain of Centene's top executives with violations of the Securities Exchange Act of 1934.If you suf ...

NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against iRobot Corporation (“iRobot” or “the Company”) (NASDAQ: IRBT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired iRobot secur ...